India’s Glenmark Collaborates With Others For HIV-Related Drug
This article was originally published in PharmAsia News
Glenmark Pharmaceuticals announced collaboration with other Indian drug makers to develop an HIV drug with several applications beyond the disease itself. The firm expects by 2010 to be able to file for U.S. approval of its crofelemer for treating several ailments, including diarrhea associated with HIV. The ability to file for the drug resulted from collaboration between Napo Pharmaceuticals and Salex Pharmaceuticals. Glenmark expects the drug to be worth $80 million in the HIV market. (Click here for more
You may also be interested in...
Novartis seems to have accepted the fact that the indication granted for Piqray in the EU means there is little scope for the advanced breast cancer drug to be used in markets such as the UK.
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
Latest EU company news: Sanofi grows OTC portfolio in France and Italy with ColdZyme; Germany's WindStar Medical gets UK owners; and France's Ipsen continues to fell effects of COVID-19 on sales.